Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Di Leo

Showing results (11-20 of 187) with videos related to

Pageof 19
Sort By:
Breast (Edinburgh, Scotland)|December 17, 2019
Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancerAmelia McCartney, Matteo Benelli, Angelo Di Leo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancerAngelo Di Leo, Harry Bleiberg, Marc Buyse
Breast (Edinburgh, Scotland)|April 13, 2010
Management of triple negative breast cancerCatherine Oakman, Giuseppe Viale, Angelo Di Leo
Oncotarget|October 23, 2018
Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?Amelia McCartney, Angelo Di Leo, Luca Malorni
Breast Cancer Research and Treatment|June 16, 2010
Re-searching anthracycline therapyCatherine Oakman, Erica Moretti, Angelo Di Leo
Current Opinion in Oncology|September 5, 2014
Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapyIlenia Migliaccio, Angelo Di Leo, Luca Malorni
The Lancet. Oncology|July 8, 2015
Continued value of adjuvant anthracyclines as treatment for early breast cancerNatalie Turner, Laura Biganzoli, Angelo Di Leo
Current Opinion in Oncology|August 29, 2009
Predicting anthracycline benefit: have we made any progress?Erica Moretti, Catherine Oakman, Angelo Di Leo
Cancer Treatment Reviews|December 10, 2002
Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancerFatima Cardoso, Angelo Di Leo, Martine J Piccart
Bulletin Du Cancer|April 9, 2008
[HER2 and topoisomerase II alpha: useful clinical markers in breast cancer]Denis Larsimont, Virginie Durbecq, Ahmad Awada, et al.
Pageof 19

Showing results (11-20 of 187) with videos related to

Sort By:
Pageof 19
Breast (Edinburgh, Scotland)|December 17, 2019
Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancerAmelia McCartney, Matteo Benelli, Angelo Di Leo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2003
Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancerAngelo Di Leo, Harry Bleiberg, Marc Buyse
Breast (Edinburgh, Scotland)|April 13, 2010
Management of triple negative breast cancerCatherine Oakman, Giuseppe Viale, Angelo Di Leo
Oncotarget|October 23, 2018
Palbociclib to reverse endocrine resistance in breast cancer: a TREnd in the right direction?Amelia McCartney, Angelo Di Leo, Luca Malorni
Breast Cancer Research and Treatment|June 16, 2010
Re-searching anthracycline therapyCatherine Oakman, Erica Moretti, Angelo Di Leo
Current Opinion in Oncology|September 5, 2014
Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapyIlenia Migliaccio, Angelo Di Leo, Luca Malorni
The Lancet. Oncology|July 8, 2015
Continued value of adjuvant anthracyclines as treatment for early breast cancerNatalie Turner, Laura Biganzoli, Angelo Di Leo
Current Opinion in Oncology|August 29, 2009
Predicting anthracycline benefit: have we made any progress?Erica Moretti, Catherine Oakman, Angelo Di Leo
Cancer Treatment Reviews|December 10, 2002
Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancerFatima Cardoso, Angelo Di Leo, Martine J Piccart
Bulletin Du Cancer|April 9, 2008
[HER2 and topoisomerase II alpha: useful clinical markers in breast cancer]Denis Larsimont, Virginie Durbecq, Ahmad Awada, et al.
Pageof 19